A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Treeline Biosciences, Inc.
Bayer
Shanghai Henlius Biotech
Pfizer
Eli Lilly and Company
Pfizer
Boehringer Ingelheim
Astellas Pharma Inc
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Fate Therapeutics
Alterome Therapeutics, Inc.
Hoffmann-La Roche
Memorial Sloan Kettering Cancer Center
Pfizer
Erasca, Inc.
Incyte Corporation
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Gustave Roussy, Cancer Campus, Grand Paris
BeOne Medicines
AstraZeneca
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Pfizer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Quanta Therapeutics
Dana-Farber Cancer Institute
Vanderbilt-Ingram Cancer Center
R-Pharm
Chugai Pharmaceutical
Tizona Therapeutics, Inc
Genentech, Inc.
Merck Sharp & Dohme LLC
Revolution Medicines, Inc.
M.D. Anderson Cancer Center
Boehringer Ingelheim
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Chugai Pharmaceutical
Quanta Therapeutics
PAQ Therapeutics, Inc.
Incyte Corporation
GlaxoSmithKline
City of Hope Medical Center
Bristol-Myers Squibb
Fate Therapeutics
University of Chicago
C4 Therapeutics, Inc.